Antithrombotic therapy in patients with complex percutaneous coronary intervention

Review published in Interv Cardiol Clin (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosLarrubia Valle et al. · Interventional cardiology clinics, 2024

Abstract

Managing antithrombotic therapy in patients undergoing complex and high-risk in indicated patients, including those treated with complex percutaneous coronary intervention (PCI) or presenting with cardiogenic shock (CS), is challenging. This review highlights the critical role of antithrombotic therapy, during and after PCI, to optimize the efficacy while minimizing risks. Unfractionated heparin remains the mainstay anticoagulant for complex PCI and CS, with bivalirudin as a potential safer alternative. Cangrelor offers consistent antiplatelet effects, especially when timely absorption of oral agents is uncertain.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Indexed MeSH termsHumansPercutaneous Coronary InterventionShock, CardiogenicFibrinolytic AgentsPlatelet Aggregation InhibitorsAnticoagulantsHirudinsAdenosine MonophosphateHeparinPeptide FragmentsRecombinant Proteins

Resumen

Review of antithrombotic therapy options for complex PCI patients including bivalirudin (leech-derived).

Por qué esto importa para la hirudoterapia

This review examines antithrombotic therapy management during and after complex percutaneous coronary intervention (PCI) and in cardiogenic shock, noting that unfractionated heparin remains the mainstay anticoagulant while bivalirudin is discussed as a potentially safer alternative. The abstract does not mention leeches, hirudin, the leech secretome, or any leech-derived intervention. No defensible connection to hirudotherapy or ASH's domain exists based on this abstract alone; the focus is entirely on pharmacological antithrombotic strategies in interventional cardiology, and any link would require external knowledge not present in the source text.

Citación

Antithrombotic therapy in patients with complex percutaneous coronary intervention.

Larrubia Valle et al. · Interventional cardiology clinics, 2024

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Bivalirudin Dermatological Applications Dermatology Otolaryngology Post-Thrombotic Syndrome Hemostasis

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026